🇺🇸 FDA
Patent

US 8940300

Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods

granted A61KA61K2039/505A61K39/39541

Quick answer

US patent 8940300 (Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods) held by ADHERON THERAPEUTICS, INC. expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ADHERON THERAPEUTICS, INC.
Grant date
Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K39/39541, A61K39/3955, A61K45/06